Study of a radioactive drug for advanced solid tumors
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer that has spread or cannot be removed with surgery, and standard treatments have stopped working.
- You must be 18 years or older (75 or younger for the first part of the study).
- Your overall health should be good enough to perform daily activities without much help (ECOG score 0 or 1).
- You need to have at least one tumor that can be measured on scans.
- You must be willing to provide a tissue sample from your tumor (either from a past biopsy or a new one).
- You cannot have serious heart, lung, or other uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
This trial tests a new radioactive drug, Lutetium-177 FAP-75, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and deliver radiation directly to cancer cells, potentially slowing tumor growth.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This early-stage trial tests a new cancer drug called BL-ARC002 in patients whose advanced or spread cancers (solid tumors) have not responded to standard treatments. The drug is an antibody designed to help the immune system fight cancer.
This trial tests an investigational drug called BL-ARC002 for people with advanced or metastatic cancers of the esophagus, stomach, colon, rectum, or other solid tumors. The goal is to see if it is safe and effective in treating these cancers.
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.